Ji‐Youn Han

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Dong‐Wan Kim, Enriqueta Felip et al. · The Lancet · 2015 · 6.5K citations

Medicine, Oncology, Pharmacology +14

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 997 citations · Full text

Medicine, Oncology, Pharmacology +15

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2018 · 976 citations · Full text

Medicine, Oncology, Pharmacology +13

Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations

Paul K. Paik, Enriqueta Felip, Rémi Veillon et al. · New England Journal of Medicine · 2020 · 854 citations · Full text

Medicine, Oncology, Pharmacology +15

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Ji‐Youn Han, Keunchil Park, Sang‐We Kim et al. · Journal of Clinical Oncology · 2012 · 735 citations

Medicine, Oncology, Pharmacology +11